科微学术

微生物学通报

肠道菌群与肝细胞癌相关研究的文献计量学分析
作者:
基金项目:

湖南省教育厅项目(21C0047)


Bibliometric analysis of studies relating gut microbiota to hepatocellular carcinoma
Author:
  • 摘要
  • | |
  • 访问统计
  • |
  • 参考文献 [43]
  • |
  • 相似文献 [20]
  • | | |
  • 文章评论
    摘要:

    【背景】肠道菌群与肝细胞癌的关系密切,对肝脏代谢和免疫产生影响。肠道菌群与肝细胞癌的相关研究引起了持续关注。【目的】分析2003–2023年近20年国内外在肠道菌群与肝细胞癌研究领域的发展趋势、研究现状和热点,为该领域的研究者提供更全面、直观的参考。【方法】分别检索Web of Science Core Collection (WoSCC)数据库和中国知网(China national knowledge infrastructure, CNKI)数据库中肠道菌群与肝细胞癌研究领域的相关文献,利用VOSviewer1.6.19、CiteSpace6.1.R6进行文献计量分析。【结果】分别从WoSCC数据库中检索出符合条件的英文文章659篇,CNKI数据库中检索出符合条件的中文文献70篇,英文文献数量和被引次数逐年增加,中文发文数量总体也呈上升的趋势。中国在发文数量和国际合作方面领先,而美国在被引次数和国际合作方面占优。最有影响力的研究机构为University of California San Diego,最有影响力的学者/团队是Elinav Eran团队,发文最多的期刊为International Journal of Molecular Sciences。关键词共现分析发现,肝细胞癌的发病机制、肠道菌群与非酒精性脂肪性肝病发生发展的关系和以肠道菌群为靶点的肝细胞癌治疗方案是该领域的研究热点,关键词突现显示“gut microbiome”和“immune checkpoint inhibitor”是当前该领域的研究前沿。【结论】本研究从文献计量学角度深入分析了肠道菌群与肝细胞癌关系的研究现状和发展趋势,为研究者在该领域深入挖掘热点和前沿、选择合适的期刊和合作伙伴提供指导。

    Abstract:

    [Background] Gut microbiota is closely associated with hepatocellular carcinoma, impacting liver metabolism and immune responses. Ongoing attention is drawn to the study of gut microbiota-related mechanisms and treatment strategies. [Objective] Analyzing the trends, current status, and hotspots in domestic and international research on gut microbiota and hepatocellular carcinoma from 2003 to 2023, aiming to provide comprehensive and intuitive references for researchers in this field. [Methods] The articles about gut microbiota and hepatocellular carcinoma were retrieved from the Web of Science Core Collection (WoSCC) and China National Knowledge Infrastructure (CNKI). VOSviewer1.6.19 and CiteSpace6.1.R6 were used for bibliometric analysis. [Results] A total of 659 eligible English publications were retrieved from the WoSCC, and 70 Chinese publications meeting the criteria were screened out from the CNKI. The annual count and citation frequency of English publications showed an increasing trend, and the total number of Chinese publications also exhibited a rising trend. China was a leading country in terms of the publication number and international collaborations, while the United States exceled in citation frequency and international partnerships. The most influential research institution was the University of California San Diego, and the most impactful scholar/team identified was the Elinav Eran team. The International Journal of Molecular Sciences was the journal with the largest publication number. The co-occurrence analysis of keywords revealed that the research hotspots included the mechanisms of hepatocellular carcinoma occurrence, the relationship between gut microbiota and non-alcoholic fatty liver disease progression, and hepatocellular carcinoma treatment strategies targeting gut microbiota. The keyword burst analysis highlighted gut microbiome and immune checkpoint inhibitor as the current research frontiers in this field. [Conclusion] This study, from the perspective of bibliometrics, comprehensively analyzed the current status and development trends of the relationship between gut microbiota and hepatocellular carcinoma, and offered guidance for researchers in this field to delve into hotspots and frontiers and to choose suitable journals and collaborators.

    参考文献
    [1] FORNER A, REIG M, BRUIX J. Hepatocellular carcinoma[J]. Lancet, 2018, 391(10127): 1301-1314.
    [2] SUNG H, FERLAY J, SIEGEL RL, LAVERSANNE M, SOERJOMATARAM I, JEMAL A, BRAY F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA: a Cancer Journal for Clinicians, 2021, 71(3): 209-249.
    [3] KIM E, VIATOUR P. Hepatocellular carcinoma: old friends and new tricks[J]. Experimental & Molecular Medicine, 2020, 52: 1898-1907.
    [4] ZHOU A, TANG L, ZENG S, LEI YY, YANG SM, TANG B. Gut microbiota: a new piece in understanding hepatocarcinogenesis[J]. Cancer Letters, 2020, 474: 15-22.
    [5] YOUNG VB. The role of the microbiome in human health and disease: an introduction for clinicians[J]. British Medical Journal (BMJ), 2017, 356: j831.
    [6] LIU TT, YANG LP, MAO HM, MA F, WANG YY, ZHAN YL. Knowledge domain and emerging trends in podocyte injury research from 1994 to 2021: a bibliometric and visualized analysis[J]. Frontiers in Pharmacology, 2021, 12: 772386.
    [7] LIAO ZX, WEI W, YANG ML, KUANG XY, SHI J. Academic publication of neurodegenerative diseases from a bibliographic perspective: a comparative scientometric analysis[J]. Frontiers in Aging Neuroscience, 2021, 13: 722944.
    [8] WU HY, LI YQ, TONG LJ, WANG YL, SUN ZM. Worldwide research tendency and hotspots on hip fracture: a 20-year bibliometric analysis[J]. Archives of Osteoporosis, 2021, 16(1): 73.
    [9] van ECK NJ, WALTMAN L. Software survey: VOSviewer, a computer program for bibliometric mapping[J]. Scientometrics, 2010, 84(2): 523-538.
    [10] 陈悦, 陈超美, 刘则渊, 胡志刚, 王贤文. CiteSpace知识图谱的方法论功能[J]. 科学学研究, 2015, 33(2): 242-253.
    CHEN Y, CHEN CM, LIU ZY, HU ZG, WANG XW. The methodology function of CiteSpace mapping knowledge domains[J]. Studies in Science of Science, 2015, 33(2): 242-253 (in Chinese).
    [11] BAJAJ JS, HEUMAN DM, HYLEMON PB, SANYAL AJ, WHITE MB, MONTEITH P, NOBLE NA, UNSER AB, DAITA K, FISHER AR, SIKAROODI M, GILLEVET PM. Altered profile of human gut microbiome is associated with cirrhosis and its complications[J]. Journal of Hepatology, 2014, 60(5): 940-947.
    [12] de MINICIS S, RYCHLICKI C, AGOSTINELLI L, SACCOMANNO S, CANDELARESI C, TROZZI L, MINGARELLI E, FACINELLI B, MAGI G, PALMIERI C, MARZIONI M, BENEDETTI A, SVEGLIATI-BARONI G. Dysbiosis contributes to fibrogenesis in the course of chronic liver injury in mice[J]. Hepatology, 2014, 59(5): 1738-1749.
    [13] SCHNABL B, BRENNER DA. Interactions between the intestinal microbiome and liver diseases[J]. Gastroenterology, 2014, 146(6): 1513-1524.
    [14] HENAO-MEJIA J, ELINAV E, JIN CC, HAO LM, MEHAL WZ, STROWIG T, THAISS CA, KAU AL, EISENBARTH SC, JURCZAK MJ, CAMPOREZ JP, SHULMAN GI, GORDON JI, HOFFMAN HM, FLAVELL RA. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity[J]. Nature, 2012, 482: 179-185.
    [15] TRIPATHI A, DEBELIUS J, BRENNER DA, KARIN M, LOOMBA R, SCHNABL B, KNIGHT R. The gut-liver axis and the intersection with the microbiome[J]. Nature Reviews Gastroenterology & Hepatology, 2018, 15: 397-411.
    [16] TACKE F, WEISKIRCHEN R. Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH)-related liver fibrosis: mechanisms, treatment and prevention[J]. Annals of Translational Medicine, 2021, 9(8): 729.
    [17] JUST S, MONDOT S, ECKER J, WEGNER K, RATH E, GAU L, STREIDL T, HERY-ARNAUD G, SCHMIDT S, LESKER TR, BIETH V, DUNKEL A, STROWIG T, HOFMANN T, HALLER D, LIEBISCH G, GÉRARD P, ROHN S, LEPAGE P, CLAVEL T. The gut microbiota drives the impact of bile acids and fat source in diet on mouse metabolism[J]. Microbiome, 2018, 6(1): 134.
    [18] CHU HK, DUAN Y, YANG L, SCHNABL B. Small metabolites, possible big changes: a microbiota-centered view of non-alcoholic fatty liver disease[J]. Gut, 2019, 68(2): 359-370.
    [19] HEYMANN F, TACKE F. Immunology in the liver: from homeostasis to disease[J]. Nature Reviews Gastroenterology & Hepatology, 2016, 13: 88-110.
    [20] RAMANAN D, PRATAMA A, ZHU YY, VENEZIA O, SASSONE-CORSI M, CHOWDHARY K, GALVÁN- PEÑA S, SEFIK E, BROWN C, GÉLINEAU A, MATHIS D, BENOIST C. Regulatory T cells in the face of the intestinal microbiota[J]. Nature Reviews Immunology, 2023, 23: 749-762.
    [21] BIGORGNE AE, JOHN B, EBRAHIMKHANI MR, SHIMIZU-ALBERGINE M, CAMPBELL JS, CRISPE IN. TLR4-dependent secretion by hepatic stellate cells of the neutrophil-chemoattractant CXCL1 mediates liver response to gut microbiota[J]. PLoS One, 2016, 11(3): e0151063.
    [22] SANDAHL TD, GRØNBAEK H, MØLLER HJ, STØY S, THOMSEN KL, DIGE AK, AGNHOLT J, HAMILTON-DUTOIT S, THIEL S, VILSTRUP H. Hepatic macrophage activation and the LPS pathway in patients with alcoholic hepatitis: a prospective cohort study[J]. The American Journal of Gastroenterology, 2014, 109(11): 1749-1756.
    [23] RODERBURG C, LUEDDE T. The role of the gut microbiome in the development and progression of liver cirrhosis and hepatocellular carcinoma[J]. Gut Microbes, 2014, 5(4): 441-445.
    [24] PETRASEK J, MANDREKAR P, SZABO G. Toll-like receptors in the pathogenesis of alcoholic liver disease[J]. Gastroenterology Research and Practice, 2010, 2010: 710381.
    [25] YU LX, YAN HX, LIU Q, YANG W, WU HP, DONG W, TANG L, LIN Y, HE YQ, ZOU SS, WANG C, ZHANG HL, CAO GW, WU MC, WANG HY. Endotoxin accumulation prevents carcinogen-induced apoptosis and promotes liver tumorigenesis in rodents[J]. Hepatology, 2010, 52(4): 1322-1333.
    [26] 蔡政, 杨勤. 中医药调节肠道菌群治疗肝细胞癌的研究进展[J]. 光明中医, 2021, 36(23): 4090-4093. CAI Z, YANG Q. Research progress of traditional Chinese medicine regulating intestinal flora in the treatment of hepatocellular carcinoma[J]. Guangming Journal of Chinese Medicine, 2021, 36(23): 4090-4093 (in Chinese).
    [27] 孙蒋, 罗静雯, 姚文杰, 骆晓婷, 苏辰霖, 魏颖慧. 大黄素对急性肾损伤大鼠肠道菌群的调节作用[J]. 中国中药杂志, 2019, 44(4): 758-764. SUN J, LUO JW, YAO WJ, LUO XT, SU CL, WEI YH. Effect of emodin on gut microbiota of rats with acute kidney failure[J]. China Journal of Chinese Materia Medica, 2019, 44(4): 758-764 (in Chinese).
    [28] 兰景彬, 潘克俭, 汪宏, 旷喜. 大黄素抑制LPS诱发的结肠癌转移的研究[J]. 天然产物研究与开发, 2017, 29(12): 2044-2049, 2055. LAN JB, PAN KJ, WANG H, KUANG X. The inhibition of emodin on metastasis of colon cancer induced by LPS[J]. Natural Product Research and Development, 2017, 29(12): 2044-2049, 2055 (in Chinese).
    [29] 于雷, 孙超, 张曼旭. 灵芝多糖对HepG2细胞诱导的肝癌小鼠肠道菌群及其菌群代谢功能的调节作用[J]. 实用肝脏病杂志, 2021, 24(4): 476-479. YU L, SUN C, ZHANG MX. Regulation of intestinal floras and their metabolism functions by ganoderma lucidum plysaceharide in mice with HepG2 cell-induced implanted cancer[J]. Journal of Practical Hepatology, 2021, 24(4): 476-479 (in Chinese).
    [30] CAO Y, XU XW, LIU SJ, HUANG LF, GU J. Ganoderma: a cancer immunotherapy review[J]. Frontiers in Pharmacology, 2018, 9: 1217.
    [31] AKASH MSH, FIAYYAZ F, REHMAN K, SABIR S, RASOOL MH. Gut microbiota and metabolic disorders: advances in therapeutic interventions[J]. Critical Reviews in Immunology, 2019, 39(4): 223-237.
    [32] PETRESCU M, VLAICU SI, CIUMĂRNEAN L, MILACIU MV, MĂRGINEAN C, FLOREA M, VESA ȘC, POPA M. Chronic inflammation-a link between nonalcoholic fatty liver disease (NAFLD) and dysfunctional adipose tissue[J]. Medicina, 2022, 58(5): 641.
    [33] CARICILLI AM, SAAD MJA. The role of gut microbiota on insulin resistance[J]. Nutrients, 2013, 5(3): 829-851.
    [34] ZHANG CH, SHENG JQ, SARSAIYA S, SHU FX, LIU TT, TU XY, MA GQ, XU GL, ZHENG HX, ZHOU LF. The anti-diabetic activities, gut microbiota composition, the anti-inflammatory effects of Scutellaria-coptis herb couple against insulin resistance-model of diabetes involving the toll-like receptor 4 signaling pathway[J]. Journal of Ethnopharmacology, 2019, 237: 202-214.
    [35] SAAD MJA, SANTOS A, PRADA PO. Linking gut microbiota and inflammation to obesity and insulin resistance[J]. Physiology, 2016, 31(4): 283-293.
    [36] LI R, ZHOU R, WANG H, LI WD, PAN MX, YAO XQ, ZHAN WQ, YANG SB, XU LJ, DING YQ, ZHAO L. Gut microbiota-stimulated cathepsin K secretion mediates TLR4-dependent M2 macrophage polarization and promotes tumor metastasis in colorectal cancer[J]. Cell Death & Differentiation, 2019, 26: 2447-2463.
    [37] LLOVET JM, WILLOUGHBY CE, SINGAL AG, GRETEN TF, HEIKENWÄLDER M, EL-SERAG HB, FINN RS, FRIEDMAN SL. Nonalcoholic steatohepatitis- related hepatocellular carcinoma: pathogenesis and treatment[J]. Nature Reviews Gastroenterology & Hepatology, 2023, 20: 487-503.
    [38] KANG Y, CAI Y. Gut microbiota and hepatitis-B- virus-induced chronic liver disease: implications for faecal microbiota transplantation therapy[J]. The Journal of Hospital Infection, 2017, 96(4): 342-348.
    [39] KHORUTS A, RANK KM, NEWMAN KM, VISKOCIL K, VAUGHN BP, HAMILTON MJ, SADOWSKY MJ. Inflammatory Bowel Disease Affects the Outcome of Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection[J]. Clinical Gastroenterology and Hepatology: the Official Clinical Practice Journal of the American Gastroenterological Association, 2016, 14(10): 1433-1438.
    [40] FERRERE G, WRZOSEK L, CAILLEUX F, TURPIN W, PUCHOIS V, SPATZ M, CIOCAN D, RAINTEAU D, HUMBERT L, HUGOT C, GAUDIN F, NOORDINE ML, ROBERT V, BERREBI D, THOMAS M, NAVEAU S, PERLEMUTER G, CASSARD AM. Fecal microbiota manipulation prevents dysbiosis and alcohol-induced liver injury in mice[J]. Journal of Hepatology, 2017, 66(4): 806-815.
    [41] BAJAJ JS, FAGAN A, GAVIS EA, KASSAM Z, SIKAROODI M, GILLEVET PM. Long-term outcomes of fecal microbiota transplantation in patients with cirrhosis[J]. Gastroenterology, 2019, 156(6): 1921-1923.e3.
    [42] DELAUNE V, ORCI LA, LACOTTE S, PELOSO A, SCHRENZEL J, LAZAREVIC V, TOSO C. Fecal microbiota transplantation: a promising strategy in preventing the progression of non-alcoholic steatohepatitis and improving the anti-cancer immune response[J]. Expert Opinion on Biological Therapy, 2018, 18(10): 1061-1071.
    引证文献
    网友评论
    网友评论
    分享到微博
    发 布
引用本文

陈世杰,孙其,陈晚平,杨尽晖. 肠道菌群与肝细胞癌相关研究的文献计量学分析[J]. 微生物学通报, 2024, 51(8): 3201-3226

复制
分享
文章指标
  • 点击次数:148
  • 下载次数: 446
  • HTML阅读次数: 291
  • 引用次数: 0
历史
  • 收稿日期:2023-11-15
  • 最后修改日期:2024-01-30
  • 在线发布日期: 2024-08-20
  • 出版日期: 2024-08-20
文章二维码